Business UpdateMay 14, 2026, 05:20 PM
LIXTE Expands Ovarian Cancer Trial, Reports Favorable LB-100 Results
AI Summary
LIXTE Biotechnology Holdings announced the filing of its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2026. The company highlighted significant progress in advancing its lead compound, LB-100, including the expansion of its ovarian cancer trial following favorable safety results with GSK's dostarlimab. Additionally, LIXTE reported continued growth and strategic development of its Liora Technologies Europe subsidiary, which focuses on proton therapy solutions. The company also presented favorable preliminary results for the LB-100 and dostarlimab combination at a recent conference.
Key Highlights
- Expanded ovarian cancer trial for LB-100 after confirming favorable safety profile with dostarlimab.
- Continued patient enrollment in the expanded ovarian cancer trial.
- Liora Technologies Europe subsidiary showed continued growth and advanced integration.
- Presented favorable preliminary results for LB-100 in combination with dostarlimab.
- Evaluating strategic expansion opportunities and complementary oncology assets.
- Sponsored inaugural Good Health: Mind, Body & Soul Summit.
Price Impact
More from LIXT